 |
| CrossRef Text and Data Mining |
| Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining. |
| Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease |
| Kai-Chun Wu, Zhi Hua Ran, Xiang Gao, Minhu Chen, Jie Zhong, Jian-Qiu Sheng, Michael A Kamm, Simon Travis, Kori Wallace, Nael M Mostafa, Marisa Shapiro, Yao Li, Roopal B Thakkar, Anne M Robinson |
|
Intest Res. 2016;14(2):152-163. Published online April 27, 2016 DOI: https://doi.org/10.5217/ir.2016.14.2.152 |
|
Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease Intestinal Research. 2016;14(2):152  Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn's Disease: The CHARM Trial Yearbook of Gastroenterology. 2007;2007:120 INDUCTION AND MAINTENANCE OF CLINICAL RESPONSE AND REMISSION WITH CERTOLIZUMAB PEGOL IN PATIENTS WITH INFLAMMATORY OR FISTULISING CROHN'S DISEASE: A REFERRAL CENTER EXPERIENCE OF COMPASSIONATE USE Digestive and Liver Disease. 2009;41:S126 Exam 2: Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped Gastroenterology. 2012;142(1):e31 Su2084 Efficacy of Certolizumab Pegol Induction and Maintenance Therapy in Patients With Crohn's Disease Not in Remission Following Active or Placebo Induction Gastroenterology. 2012;142(5):S-565 Su1126 In Patients With Crohn's Disease, Concomitant Enteral Nutrition Reduces the Loss of Response to Adalimumab Maintenance Therapy Gastroenterology. 2014;146(5):S-382 Sa1968 Post-Induction Adalimumab Drug Levels Predict Clinical and Laboratory Remission at Week 24 in Patients With Crohn's Disease Gastroenterology. 2016;150(4):S419 Su1127 In Patients With Crohn's Disease, Timing of Switching From Infliximab Maintenance Therapy to Adalimumab Affects Patients' Prognosis Gastroenterology. 2014;146(5):S-382 Adalimumab maintenance therapy improves quality of life in patients with Crohn's disease Nature Reviews Gastroenterology & Hepatology. 2009;6(3):129-129 Adalimumab sustains steroid-free remission after 3years of therapy for Crohn's disease Yearbook of Medicine. 2012;2012:393-394 |
